Home › Companies › OCS

Oculis Holding

OCS Lead: Phase 3 ★ Read the deep dive → 1 Biotech Distilled article ↓

Neurology Ophthalmology Protein Small Molecule

Most recent annual filing: 2026-03-04

Pipeline (5 active programs)

OCS-01

Diabetic Macular Edema Phase 3 topical

Licaminlimab

OCS-02

Protein Target: TNFα

Dry Eye Disease Phase 2 topical Novartis

Privosegtor

OCS-05

Optic Neuritis Phase 3 Accure Therapeutics SL
Non-Arteritic Anterior Ischemic Optic Neuropathy Phase 3 Accure Therapeutics SL
Multiple Sclerosis Preclinical Accure Therapeutics SL

Technology platforms

OPTIREACH

Proprietary cyclodextrin-based solubilizing formulation technology that improves solubility of lipophilic drugs, increases residence time on the eye surface, and enables topical delivery of therapeutics to the posterior segment of the eye; focus area: ophthalmic diseases including DME

Biotech Distilled coverage (1)

2026-06-05 Oculis Holding AG (OCS) — Scientific Deep Dive for Privosegtor, Licaminlimab, and the OCS-01 Wreckage

Articles open on Substack. Some deep dives are subscriber-only.